UnitedHealth Group (UNH) stock recovers after CEO departure, The company to offer $1M annual base salary for new leadership.

As regulatory landscapes shift with administration changes, compliance programs face heightened scrutiny. BDO's Kenneth Koch ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

"It supports and provides free counselling and support services to adult survivors of childhood sexual abuse right across all the six counties of North Wales, and last year was the charity's fortieth ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK Plc agreed to buy an experimental medicine for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies.

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...

LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.